Vaccines for the 21st century
暂无分享,去创建一个
Rino Rappuoli | Ennio De Gregorio | R. Rappuoli | E. De Gregorio | I. Delany | Isabel Delany | Isabel Delany
[1] Eva K. Lee,et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.
[2] Timothy B. Stockwell,et al. Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics , 2013, Science Translational Medicine.
[3] G. Aronoff,et al. Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis , 2012, Clinical and Vaccine Immunology.
[4] B. Guy,et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. , 2009, The American journal of tropical medicine and hygiene.
[5] R. Betts,et al. Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans , 2010, Clinical and Vaccine Immunology.
[6] R. Betts,et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. , 2013, JAMA.
[7] Stefan H E Kaufmann,et al. Future vaccination strategies against tuberculosis: thinking outside the box. , 2010, Immunity.
[8] Andrea Sutherland,et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. , 2011, American journal of obstetrics and gynecology.
[9] J. Kublin,et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.
[10] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[11] H. Rammensee,et al. Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.
[12] Franz X Heinz,et al. Flaviviruses and flavivirus vaccines. , 2012, Vaccine.
[13] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[14] D. Pace. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. , 2009, Current opinion in molecular therapeutics.
[15] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[16] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[17] S. Keam,et al. Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™] , 2012, BioDrugs.
[18] Eileen M. Crimmins,et al. Inflammatory Exposure and Historical Changes in Human Life-Spans , 2004, Science.
[19] A. Eggermont,et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Lang,et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.
[21] S. Lawn,et al. Diagnosis of extrapulmonary tuberculosis using the Xpert® MTB/RIF assay , 2012, Expert review of anti-infective therapy.
[22] Adam Godzik,et al. A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.
[23] H. Poulet,et al. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. , 2007, Vaccine.
[24] J. Lisziewicz,et al. Cytokine-adjuvanted HIV-DNA vaccination strategies , 2006, Springer Seminars in Immunopathology.
[25] S. Draper,et al. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets , 2013, Expert review of vaccines.
[26] U. Baxa,et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.
[27] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[28] R. Chanock,et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.
[29] Marion Becker,et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.
[30] S. Kaufmann,et al. Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? , 2012, PLoS pathogens.
[31] B. Polack,et al. Live-attenuated bacteria as a cancer vaccine vector , 2013, Expert review of vaccines.
[32] Cinque S. Soto,et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.
[33] S. Lockhart,et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.
[34] B. Beutler,et al. The interface between innate and adaptive immunity , 2004, Nature Immunology.
[35] K. Marsh,et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial , 2011, The Lancet. Infectious diseases.
[36] Rino Rappuoli,et al. Reverse vaccinology. , 2000, Current opinion in microbiology.
[37] G. Turner,et al. Rabies: a review. , 1993, Journal of comparative pathology.
[38] Jean C. Lee,et al. Vaccination and passive immunisation against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.
[39] G. Poste,et al. New Generation Vaccines , 1993, NATO ASI Series.
[40] M. Demoitié,et al. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. , 2013, Vaccine.
[41] Margaret A. Liu,et al. Immunologic basis of vaccine vectors. , 2010, Immunity.
[42] K. Mills,et al. Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.
[43] J. Langedijk,et al. Structure-based design for high-hanging vaccine fruits. , 2012, Advances in immunology.
[44] L. Wilkinson. Immunity , 1891, The Lancet.
[45] C. Mandl,et al. Vaccines for the twenty-first century society , 2011, Nature Reviews Immunology.
[46] V. Demicheli,et al. Vaccines for women to prevent neonatal tetanus. , 2013, The Cochrane database of systematic reviews.
[47] Saravudh Suvannadabba,et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.
[48] Donald K Carter,et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.
[49] J. McLellan,et al. Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.
[50] C. Jones,et al. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. , 2011, JAMA.
[51] W. Tompson,et al. Problems and Prospects: , 2020, Jewish Christianity.
[52] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[53] F. Guirakhoo,et al. Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.
[54] H. Rammensee,et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] M. Sanford. Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) , 2012, Drugs.
[56] H. Rammensee,et al. Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA , 2008, Journal of immunotherapy.
[57] J. Stockman. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .
[58] J. Lang,et al. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity , 2011, The Pediatric infectious disease journal.
[59] Denise A. Martin,et al. West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays , 2001, Journal of Virology.
[60] B. Romanowski. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines , 2011, Human vaccines.
[61] P. Pineau,et al. La vaccination : atout majeur dans la lutte contre le cancer du foie induit par le virus de l’hépatite B , 2010 .
[62] Shuzhao Li,et al. Systems vaccinology: Probing humanity’s diverse immune systems with vaccines , 2014, Proceedings of the National Academy of Sciences.
[63] Charles R. Newton,et al. Maternal and neonatal tetanus , 2015, The Lancet.
[64] S. Buchbinder,et al. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine , 2010, Current opinion in HIV and AIDS.
[65] E. De Gregorio,et al. Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.
[66] A. Calmette. La vaccination preventive contre la tuberculose par le "BCG" , 1927 .
[67] R. Schwartz,et al. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector , 1997, Nature Biotechnology.
[68] C. Mandl,et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.
[69] Bastian R. Angermann,et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.
[70] B. Spellberg,et al. Development of a vaccine against Staphylococcus aureus , 2011, Seminars in Immunopathology.
[71] S. Black,et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.
[72] S. Halstead,et al. Dengue vaccine development: a 75% solution? , 2012, The Lancet.
[73] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[74] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[75] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[76] M. Otto. Novel targeted immunotherapy approaches for staphylococcal infection , 2010, Expert opinion on biological therapy.
[77] K. Ohlsen,et al. Immunotherapeutic strategies to combat staphylococcal infections. , 2010, International journal of medical microbiology : IJMM.
[78] C. Rupprecht,et al. Poxvirus-vectored vaccines for rabies--a review. , 2009, Vaccine.
[79] R. Rappuoli,et al. A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[80] S. Duggan. Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®] , 2010, Drugs.
[81] A. Shane. Effectiveness of Maternal Influenza Immunization in Mothers and Infants , 2009 .
[82] A. Bouchie. GSK plows ahead with EMA malaria vaccine submission , 2013, Nature Biotechnology.
[83] M. Demoitié,et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.
[84] R. Prymula,et al. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™ , 2009, Expert review of vaccines.
[85] S. Keam,et al. Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™] , 2008, Drugs.
[86] J. Wolchok,et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. , 2011, American journal of veterinary research.
[87] T. Monath,et al. Yellow fever vaccination and pregnancy: a four-year prospective study. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[88] M. Siddiqui,et al. Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) , 2012, Drugs.
[89] V. Demicheli,et al. Vaccines for women for preventing neonatal tetanus. , 2015, The Cochrane database of systematic reviews.
[90] C. Mandl,et al. RNA: the new revolution in nucleic acid vaccines. , 2013, Seminars in immunology.
[91] D. Weiner,et al. Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants , 2013, Front. Immunol..
[92] A. Hill,et al. Viral vectors as vaccine platforms: deployment in sight. , 2011, Current opinion in immunology.
[93] Thomas A. Smith,et al. Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission , 2012, PloS one.
[94] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[95] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[96] R. Proctor. Is there a future for a Staphylococcus aureus vaccine? , 2012, Vaccine.
[97] Ross D. Shachter,et al. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. , 2009, The Journal of infectious diseases.
[98] K. Garver,et al. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. , 2005, Diseases of aquatic organisms.
[99] Brigitte Colau,et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.
[100] C. Healy,et al. Vaccines in pregnant women and research initiatives. , 2012, Clinical obstetrics and gynecology.
[101] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[102] J. Mascola,et al. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.
[103] R. Betts,et al. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. , 2012, Vaccine.
[104] Thomas Krucker,et al. Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.
[105] B. Walker,et al. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. , 2013, Vaccine.
[106] S. Halstead,et al. Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.
[107] S. Kaufmann. Tuberculosis vaccine development: strength lies in tenacity. , 2012, Trends in immunology.
[108] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[109] S. Reef,et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001-2008. , 2011, The Journal of infectious diseases.
[110] N. Sardesai,et al. Electroporation delivery of DNA vaccines: prospects for success. , 2011, Current opinion in immunology.
[111] Antonio Lanzavecchia,et al. Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.
[112] D. Weiner,et al. Clinical applications of DNA vaccines: current progress. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[113] N. Sardesai,et al. Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.
[114] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[115] Kwaku Poku Asante,et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data , 2013, The Lancet. Infectious diseases.
[116] William R Schief,et al. Advances in structure-based vaccine design. , 2013, Current opinion in virology.
[117] J. Venter,et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.
[118] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[119] K. Jansen,et al. Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". , 2013, Vaccine.